Gene Cathey, MD
Family Medicine · Magee, MSNPI 1811918246
Payments from drug & device makers
Across 465 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$1K
- Novo Nordisk$785
- AbbVie$616
- Pfizer$493
- GSK$476
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,879100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $1,305 |
| Amgen | 67 | $1,026 |
| Novo Nordisk | 38 | $785 |
| AbbVie(2 entities) | 42 | $616 |
| Pfizer | 34 | $493 |
| GSK | 37 | $476 |
| Lilly USA, LLC | 33 | $444 |
| Sanofi-aventis U.S. LLC | 16 | $304 |
| Johnson & Johnson | 21 | $286 |
| Astellas Pharma US Inc | 21 | $275 |
| Mylan Specialty L.p. | 11 | $249 |
| Novartis | 10 | $179 |
| Sumitomo Pharma America, Inc. | 12 | $177 |
| Vanda Pharmaceuticals Inc. | 7 | $167 |
| Exact Sciences | 7 | $121 |
| Boehringer Ingelheim | 7 | $121 |
| Abbott | 7 | $110 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $103 |
| Regeneron Healthcare Solutions, Inc. | 6 | $88 |
| Biohaven Pharmaceuticals, Inc. | 4 | $80 |
| Daiichi Sankyo Inc. | 5 | $79 |
| Merck | 5 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $70 |
| Sunovion Pharmaceuticals Inc. | 5 | $54 |
| Dexcom, Inc. | 2 | $32 |
| Genentech USA, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Mannkind Corporation | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $12 |
| Radius Health, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,893 in reported general payments places this provider in the 90th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 205 | $175,649 |
| OzempicSemaglutide | 147 | $162,850 |
| MounjaroTirzepatide | 124 | $135,476 |
| EliquisApixaban | 151 | $116,191 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $97,356 |
| MyrbetriqMirabegron | 101 | $62,138 |
| FarxigaDapagliflozin Propanediol | 83 | $61,552 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 76 | $57,967 |
| Repatha SureclickEvolocumab | 37 | $32,484 |
| LinzessLinaclotide | 42 | $30,460 |
| XareltoRivaroxaban | 28 | $26,700 |
| JanuviaSitagliptin Phosphate | 27 | $25,934 |
| SymbicortBudesonide/Formoterol Fumarate | 67 | $25,620 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $21,541 |
| GemtesaVibegron | 30 | $20,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $121 | $202,304236 claims |
| Novo NordiskOzempic | $785 | $162,850147 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,305 | $145,139226 claims |
| Lilly USA, LLCMounjaro | $444 | $135,476124 claims |
| PfizerEliquis | $493 | $116,191151 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $476 | $105,580120 claims |
| Astellas Pharma US IncMyrbetriq | $275 | $62,138101 claims |
| AbbVieLinzess, Synthroid | $616 | $32,71268 claims |
| Johnson & JohnsonXarelto | $286 | $26,70028 claims |
| MerckJanuvia | $70 | $25,93427 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $177 | $20,09630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Magee
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
- Keith StokesLexington$660K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.